CN116942892B - Hydrogel dressing for treating diabetes wound surface and preparation method thereof - Google Patents
Hydrogel dressing for treating diabetes wound surface and preparation method thereof Download PDFInfo
- Publication number
- CN116942892B CN116942892B CN202311100775.1A CN202311100775A CN116942892B CN 116942892 B CN116942892 B CN 116942892B CN 202311100775 A CN202311100775 A CN 202311100775A CN 116942892 B CN116942892 B CN 116942892B
- Authority
- CN
- China
- Prior art keywords
- carbon quantum
- quantum dot
- gallic acid
- hydrogel
- hydroxypropyl chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 119
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 169
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims abstract description 110
- 229940074391 gallic acid Drugs 0.000 claims abstract description 84
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 84
- 229940054190 hydroxypropyl chitosan Drugs 0.000 claims abstract description 73
- 206010052428 Wound Diseases 0.000 claims abstract description 49
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 49
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000008367 deionised water Substances 0.000 claims abstract description 29
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 29
- 239000000679 carrageenan Substances 0.000 claims abstract description 15
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 15
- 229920001525 carrageenan Polymers 0.000 claims abstract description 15
- 229940113118 carrageenan Drugs 0.000 claims abstract description 15
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 15
- 238000004132 cross linking Methods 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 9
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- -1 polytetrafluoroethylene Polymers 0.000 claims description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 5
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 4
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 2
- 239000012498 ultrapure water Substances 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 abstract description 5
- 230000000052 comparative effect Effects 0.000 description 28
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 230000002000 scavenging effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000009740 moulding (composite fabrication) Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001027 hydrothermal synthesis Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/108—Elemental carbon, e.g. charcoal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a hydrogel dressing for treating a diabetes wound and a preparation method thereof, belonging to the technical field of diabetes wound healing, and comprising the following components in parts by weight: 5-10 parts of gallic acid carbon quantum dots, 10-20 parts of hydroxypropyl chitosan, 50-60 parts of deionized water, 1-15 parts of carrageenan and 0.5-5 parts of glycerol; the hydrogel dressing for treating the diabetes wound is prepared by covalent crosslinking of gallic acid carbon quantum dots and hydroxypropyl chitosan through amide bonds; the size of the gallic acid carbon quantum dot is 1nm-8nm. The invention provides a hydrogel dressing for treating diabetes wound surfaces and a preparation method thereof, and aims to solve the problems of lack of bioactivity and poor mechanical properties.
Description
Technical Field
The invention belongs to the technical field of diabetic wound healing, and particularly relates to a hydrogel dressing for treating diabetic wound and a preparation method thereof.
Background
Diabetes is a common chronic metabolic disorder disease, and the number of patients is increasing year by year; the wound surface difficult to heal of diabetes is one of common complications of diabetes, and has the characteristics of long-term non-healing and repeated attack; when the skin of a diabetic patient is damaged, the immune disorder caused by diabetes causes the wound to be in a high-level inflammatory environment for a long time, gradually becomes chronic ulcer difficult to heal, and the improper or untimely treatment of the chronic wound surface of the diabetes can lead to amputation and even endanger life.
The wound dressing can provide a moist healing environment, prevent secondary infection of bacteria, promote wound healing and play an important role in chronic wound treatment of diabetes; common traditional dressing materials comprise medical gauze, bandages, absorbent cotton and the like, and can play a role in protecting wounds, but the traditional dressing materials still have various defects of easy adhesion with the wounds, secondary damage caused by changing auxiliary materials and the like, so the application of the novel dressing materials is widely focused; the hydrogel is a novel biomedical polymer material, can form a three-dimensional network structure through physical or chemical crosslinking, has strong water absorption performance, can keep the moist environment of a wound surface, and can prevent external bacterial infection, thereby accelerating wound healing; the hydrogel can also reduce the surface temperature of the wound and play a certain role in easing pain; meanwhile, the hydrogel has higher porosity and softness, bioactive substances or functional polymers are introduced into a special network structure of the hydrogel, so that wound healing can be promoted, advanced glycosylation end products caused by hyperglycemia are used for inducing immune cells to generate high-level active oxygen, so that oxidative stress is aggravated, normal cell death and tissue injury are caused, and therefore, the removal and inhibition of the generation of the active oxygen to reduce the oxidative stress are effective strategies for treating chronic wounds of diabetes; the natural antioxidant substances have good oxidation resistance and better biocompatibility, but most of the natural antioxidants are small molecules, and the defects of instability, short half-life of blood circulation, low bioavailability and the like usually exist in the using process.
The existing hydrogel dressing technology for treating the diabetes wound surface mainly has the following problems: first, hydrogel dressings are generally poor in mechanical properties, lacking in toughness and ductility; secondly, most hydrogel dressings are mainly used for reducing infection and relieving local symptoms, lack of biological activity and cannot effectively promote healing of diabetic wounds at a molecular level; third, some natural small molecules with outstanding oxidation resistance are difficult to prepare into hydrogels, and the application is limited.
Disclosure of Invention
Aiming at the situation, in order to overcome the defects of the prior art, the invention provides a hydrogel dressing for treating a diabetic wound surface and a preparation method thereof, and in order to solve the problem that the diabetic wound surface is difficult to heal, the invention provides a method for preparing carbon quantum dots by a hydrothermal method through natural polyphenol gallic acid, wherein the carbon quantum dots of the gallic acid and hydroxypropyl chitosan are crosslinked through amide bonds to form a covalent hydrogel network, so that the oxidation resistance and the mechanical property of the hydrogel are improved; gallic acid and hydroxypropyl chitosan have high antioxidant activity, and can play a synergistic effect in scavenging active oxygen free radicals to promote the healing of diabetic wounds.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: the invention provides a hydrogel dressing for treating a diabetes wound and a preparation method thereof, wherein the hydrogel dressing for treating the diabetes wound comprises the following components in parts by weight:
5-10 parts of gallic acid carbon quantum dots, 10-20 parts of hydroxypropyl chitosan, 50-60 parts of deionized water, 1-15 parts of carrageenan and 0.5-5 parts of glycerol;
preferably, the hydrogel dressing for treating the diabetes wound is prepared by covalent crosslinking of gallic acid carbon quantum dots and hydroxypropyl chitosan;
preferably, the size of the gallic acid carbon quantum dot is 1nm-8nm.
The invention also provides a preparation method of the hydrogel dressing for treating the diabetes wound, which comprises the following steps:
s1, dissolving gallic acid carbon quantum dot powder in ultrapure water, uniformly stirring, adding condensing agent 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide, and reacting under heating conditions to obtain gallic acid carbon quantum dot solution;
s2, adding a hydroxypropyl chitosan aqueous solution into the gallic acid carbon quantum dot solution in the step S1, uniformly stirring to form a carbon quantum dot/hydroxypropyl chitosan mixed solution, reacting under a heating condition, and performing gel forming to obtain a carbon quantum dot/hydroxypropyl chitosan hydrogel;
and S3, adding deionized water, carrageenan and glycerin into the carbon quantum dot/hydroxypropyl chitosan hydrogel obtained in the step S2, and stirring at room temperature to obtain the hydrogel dressing.
Preferably, the preparation method of the gallic acid carbon quantum dot specifically comprises the following steps:
dissolving gallic acid in absolute ethyl alcohol, stirring uniformly at room temperature, transferring the mixture into a polytetrafluoroethylene high-pressure reaction kettle, reacting under heating, naturally cooling the high-pressure reaction kettle to room temperature after the reaction is finished, centrifuging the reaction mixture, taking supernatant, removing ethanol solvent by a rotary evaporator, ultrasonically dispersing the product into deionized water, filtering the solution by a microporous membrane with the size of 0.22 mu m, dialyzing by a dialysis membrane, and finally performing vacuum freeze-drying to obtain purified gallic acid carbon quantum dot powder.
Preferably, the dosage ratio of the gallic acid to the absolute ethyl alcohol is 1g: (15-20) mL;
preferably, the heating temperature is 175-195 ℃ and the heating time is 5-10 hours;
preferably, the centrifuge speed is 8500rpm and the centrifugation time is 20min;
preferably, the cut-off of the dialysis bag is 500Da, the dialysis time is 24 hours, and the vacuum freeze-drying time is 24 hours.
Preferably, in the step S1, the concentration of the carbon quantum dots in the gallic acid carbon quantum dot solution is 1-5mg/mL;
preferably, in the step S1, the stirring temperature is 25-30 ℃ and the stirring time is 15-30min;
preferably, in the step S1, the mass ratio of the gallic acid carbon quantum dots, the condensing agent 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and the N-hydroxysuccinimide is 1:4:1.5-2;
preferably, in step S1, the reaction temperature is between 35℃and 45℃and the reaction time is between 1.6 and 2 hours.
Preferably, in step S2, the concentration of the hydroxypropyl chitosan aqueous solution is 3-10mg/mL, and the volume ratio of the carbon quantum dot solution to the hydroxypropyl chitosan aqueous solution is: 1:1.5-3;
preferably, in step S2, the heating temperature is 50 ℃ to 60 ℃ and the heating time is 8 to 12 hours.
Preferably, in step S3, the stirring temperature is 25-35 ℃ and the stirring time is 2-3h.
The beneficial effects obtained by the invention are as follows:
the invention provides a hydrogel dressing for treating diabetes wound and a preparation method thereof, which takes two antioxidant molecules of gallic acid and hydroxypropyl chitosan as raw materials, and prepares an amide bond crosslinked covalent hydrogel network through condensation reaction of carboxyl on the surface of a gallic acid carbon quantum dot and amino in a hydroxypropyl chitosan structure; according to the invention, the natural polyphenol gallic acid with high-efficiency antioxidation is used as a carbon source to prepare the gallic acid carbon quantum dot by a one-step hydrothermal method, the carbon quantum dot has extremely small particle size and molecular weight and mainly comprises carbon elements, and the carbon elements belong to biological elements and have chemical inertness, so that the carbon quantum dot has good stability, biocompatibility and low cytotoxicity, and the surface of the gallic acid carbon quantum dot is rich in hydrophilic functional groups such as hydroxyl, carboxyl and the like, so that the gallic acid carbon quantum dot has good water solubility and is easy to functionally modify; in the invention, the surfaces of the gallic acid carbon quantum dot and the hydroxypropyl chitosan both contain a plurality of phenolic hydroxyl structures, so that the gallic acid carbon quantum dot and the hydroxypropyl chitosan have good active oxygen free radical scavenging capability, and can cooperatively play an antioxidation role; simultaneously, the phenolic hydroxyl groups also endow the hydrogel with good tissue adhesiveness; the surface of the carbon quantum dot is provided with a large number of hydroxyl groups and carboxyl groups, and rich amino groups and hydroxyl groups on the hydroxypropyl chitosan main chain can form electrostatic interaction and hydrogen bond interaction, so that the crosslinking strength between the carbon quantum dot and the organic matrix is further enhanced, the hydrogel has good toughness and ductility, and the mechanical property of the hydrogel is improved; the preparation process is simple, easy to operate, suitable for large-scale preparation and has wide application prospect in the field of diabetes wound treatment.
Drawings
Fig. 1 is an SEM image of the gallic acid carbon quantum dots prepared in step S1 of example 1 of the present invention;
FIG. 2 is an SEM image of the carbon quantum dot/hydroxypropyl chitosan hydrogel prepared in example 1 of the present invention;
FIG. 3 is a stress-strain curve of hydrogels prepared according to examples 1-3 and comparative examples 1-2 of the present invention;
FIG. 4 is a graph showing the free radical scavenging efficiency of hydrogels prepared in examples 1-3 and comparative examples 1-2 according to the present invention;
FIG. 5 is a graph showing adhesion property test of hydrogels prepared in examples 1-3 and comparative examples 1-2 according to the present invention;
FIG. 6 is a graph showing cell compatibility test of hydrogels prepared in examples 1-3 and comparative examples 1-2 according to the present invention.
The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate the invention and together with the embodiments of the invention, serve to explain the invention.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and fully with reference to the accompanying drawings, in which it is evident that the embodiments described are only some, but not all embodiments of the invention; all other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the present invention. The preferred methods and materials described herein are illustrative only and should not be construed as limiting the scope of the present application.
The experimental methods in the following examples are all conventional methods unless otherwise specified; the test materials and test strains used in the examples described below, unless otherwise specified, were commercially available.
The sources of the raw materials used in the embodiment of the invention are as follows:
gallic acid (CAS: 149-91-7) was purchased from Shanghai Milin Biochemical technologies Co., ltd., brand: g823163;
hydroxypropyl chitosan (CAS: 300-03-6) was purchased from Wuhan Rana white pharmaceutical chemicals Co., ltd;
1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (CAS: 25952-53-8) available from Shanghai Keke Biotechnology Co., ltd., trade name: KH-174;
n-hydroxysuccinimide (CAS: 6066-82-6) is available from Shanghai Ala Biotechnology Co., ltd., trade name: H10933.
example 1
The hydrogel dressing for treating the diabetes wound surface comprises the following components in parts by weight: 5 parts of gallic acid carbon quantum dots, 10 parts of hydroxypropyl chitosan, 50 parts of deionized water, 1 part of carrageenan and 0.5 part of glycerol;
the preparation method of the gallic acid carbon quantum dot specifically comprises the following steps:
dissolving gallic acid in absolute ethyl alcohol according to the dosage ratio of 1g to 15mL, stirring uniformly at room temperature, transferring the mixture into a polytetrafluoroethylene high-pressure reaction kettle, heating for 5h at 175 ℃, naturally cooling the reaction kettle to room temperature, centrifuging the reaction mixture at 8500rpm for 20min, taking supernatant, removing ethanol solvent by a rotary evaporator, dispersing the product in deionized water by ultrasonic, filtering by adopting a 0.22 mu m microporous filter membrane, dialyzing for 24h by using a dialysis bag with the cutoff of 500Da, and freeze-drying for 24h in vacuum to obtain purified gallic acid carbon quantum dot powder.
The invention also provides a preparation method of the hydrogel dressing for treating the diabetes wound, which comprises the following steps:
s1, dissolving carbon quantum dot powder in 10mL of deionized water, and uniformly stirring at room temperature to obtain a carbon quantum dot solution with the concentration of 1 mg/mL; respectively weighing 40mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and 15mg of N-hydroxysuccinimide, adding into the carbon quantum dot solution, and stirring at 35 ℃ for 1.6 hours to obtain a gallic acid carbon quantum dot solution;
s2, adding 15mL of hydroxypropyl chitosan aqueous solution with the concentration of 3mg/mL into the carbon quantum dot solution in the step S1, stirring for 1.6h at 35 ℃ to form a carbon quantum dot/hydroxypropyl chitosan mixed solution, heating to 50 ℃, stirring for 9h, and performing gel forming to obtain the carbon quantum dot/hydroxypropyl chitosan hydrogel;
and S3, adding deionized water, carrageenan and glycerin into the carbon quantum dot/hydroxypropyl chitosan hydrogel obtained in the step S2, and stirring for 2 hours at room temperature to obtain the hydrogel dressing.
Example 2
The hydrogel dressing for treating the diabetes wound surface comprises the following components in parts by weight: 7 parts of gallic acid carbon quantum dots, 15 parts of hydroxypropyl chitosan, 55 parts of deionized water, 7 parts of carrageenan and 3 parts of glycerol;
the preparation method of the gallic acid carbon quantum dot specifically comprises the following steps:
dissolving gallic acid in absolute ethyl alcohol according to the dosage ratio of 1g to 17mL, stirring uniformly at room temperature, transferring the mixture into a polytetrafluoroethylene high-pressure reaction kettle, heating for 7h at 185 ℃, naturally cooling the reaction kettle to room temperature, centrifuging the reaction mixture at 8500rpm for 20min, taking supernatant, removing ethanol solvent by a rotary evaporator, dispersing the product in deionized water by ultrasonic, filtering by adopting a 0.22 mu m microporous filter membrane, dialyzing for 24h by using a dialysis bag with the cutoff of 500Da, and freeze-drying for 24h in vacuum to obtain purified gallic acid carbon quantum dot powder.
The invention also provides a preparation method of the hydrogel dressing for treating the diabetes wound, which comprises the following steps:
s1, dissolving carbon quantum dot powder in 10mL of deionized water, and uniformly stirring at room temperature to obtain a carbon quantum dot solution with the concentration of 3 mg/mL; respectively weighing 180mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and 90mg of N-hydroxysuccinimide, adding into the carbon quantum dot solution, and stirring at 40 ℃ for 1.8 hours to obtain a gallic acid carbon quantum dot solution;
s2, adding 15mL of hydroxypropyl chitosan aqueous solution with the concentration of 7mg/mL into the carbon quantum dot solution in the step S1, stirring for 30min at room temperature to form a carbon quantum dot/hydroxypropyl chitosan mixed solution, heating to 55 ℃, stirring for 9h, and performing gel molding to obtain the carbon quantum dot/hydroxypropyl chitosan hydrogel;
and S3, adding deionized water, carrageenan and glycerin into the carbon quantum dot/hydroxypropyl chitosan hydrogel obtained in the step S2, and stirring for 2.5 hours at room temperature to obtain the hydrogel dressing.
Example 3
The hydrogel dressing for treating the diabetes wound surface comprises the following components in parts by weight: 10 parts of gallic acid carbon quantum dots, 20 parts of hydroxypropyl chitosan, 60 parts of deionized water, 15 parts of carrageenan and 5 parts of glycerol;
the preparation method of the gallic acid carbon quantum dot specifically comprises the following steps:
dissolving gallic acid in absolute ethyl alcohol according to the dosage ratio of 1g to 20mL, stirring uniformly at room temperature, transferring the mixture into a polytetrafluoroethylene high-pressure reaction kettle, heating for 10 hours at 195 ℃, naturally cooling the reaction kettle to room temperature, centrifuging the reaction mixture at 8500rpm for 20 minutes, taking supernatant, removing ethanol solvent by a rotary evaporator, dispersing the product in deionized water by ultrasonic, filtering by adopting a 0.22 mu m microporous filter membrane, dialyzing for 24 hours by using a dialysis bag with the interception amount of 500Da, and performing vacuum freeze drying for 24 hours to obtain purified gallic acid carbon quantum dot powder.
The invention also provides a preparation method of the hydrogel dressing for treating the diabetes wound, which comprises the following steps:
s1, dissolving carbon quantum dot powder in 10mL of deionized water, and uniformly stirring at room temperature to obtain a carbon quantum dot solution with the concentration of 5mg/mL; respectively weighing 300mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and 113mg of N-hydroxysuccinimide, adding into the carbon quantum dot solution, and stirring at 45 ℃ for 2 hours to obtain a gallic acid carbon quantum dot solution;
s2, adding 20mL of hydroxypropyl chitosan aqueous solution with the concentration of 10mg/mL into the carbon quantum dot solution in the step S1, stirring for 30min at room temperature to form a carbon quantum dot/hydroxypropyl chitosan mixed solution, heating to 60 ℃, stirring for 12h, and performing gel molding to obtain the carbon quantum dot/hydroxypropyl chitosan hydrogel;
and S3, adding deionized water, carrageenan and glycerin into the carbon quantum dot/hydroxypropyl chitosan hydrogel obtained in the step S2, and stirring for 3 hours at room temperature to obtain the hydrogel dressing.
Comparative example 1
The comparative example provides a hydrogel dressing for treating a diabetic wound and a preparation method thereof, wherein the hydrogel dressing for treating the diabetic wound comprises the following components in parts by weight: 10 parts of hydroxypropyl chitosan, 50 parts of deionized water, 1 part of carrageenan and 0.5 part of glycerol;
the invention also provides a preparation method of the hydrogel dressing for treating the diabetes wound, which comprises the following steps:
s1, dissolving 45mg of hydroxypropyl chitosan in 15mL of deionized water, adding glutaraldehyde solution with the concentration of 1% under the stirring condition, heating to 50 ℃, stirring for 2 hours, forming gel, soaking and washing for many times by using the deionized water, and drying in vacuum for 24 hours to obtain hydroxypropyl chitosan hydrogel;
s2, adding deionized water, carrageenan and glycerin into the hydroxypropyl chitosan hydrogel obtained in the step S1, and stirring for 2 hours at room temperature to obtain the hydrogel dressing.
Comparative example 2
The hydrogel dressing for treating the diabetes wound surface comprises the following components in parts by weight: 5 parts of gallic acid, 10 parts of hydroxypropyl chitosan, 50 parts of deionized water, 1 part of carrageenan and 0.5 part of glycerol;
the invention also provides a preparation method of the hydrogel dressing for treating the diabetes wound, which comprises the following steps:
s1, dissolving gallic acid in 15mL of deionized water, and uniformly stirring at room temperature to obtain gallic acid solution with the concentration of 1 mg/mL;
s2, dissolving 45mg of hydroxypropyl chitosan in 15mL of deionized water, adding glutaraldehyde solution with the concentration of 1% under the stirring condition, adding the gallic acid solution obtained in the step S1, heating to 50 ℃, stirring for 2 hours, performing gel forming, soaking and washing with deionized water for multiple times, and performing vacuum drying for 24 hours to obtain hydroxypropyl chitosan hydrogel;
and S3, adding deionized water, carrageenan and glycerin into the hydroxypropyl chitosan hydrogel obtained in the step S2, and stirring for 2 hours at room temperature to obtain the hydrogel dressing.
Experimental example 1
In the experimental example, the gallic acid carbon quantum dots prepared in the step S1 in the preparation method of the hydrogel dressing for treating diabetes wound surface in the embodiment 1 of the invention are observed under a scanning electron microscope, fig. 1 is an SEM image of the carbon quantum dots, and it can be seen from fig. 1 that the prepared gallic acid carbon quantum dots are spherical-like nanoparticles with good dispersibility; the size range of the carbon quantum dot is 1.93 to 7.25nm by utilizing dynamic light scattering analysis, and the average particle size is 3.72+/-0.019 nm; the broader size distribution is due to the swelling process of the nanoparticles in aqueous solution and the small aggregation of hydrophilic carboxyl and hydroxyl groups abundant on the surface of the carbon dots.
Experimental example 2
In this experimental example, the gallic acid carbon quantum dot/hydroxypropyl chitosan hydrogel prepared in the embodiment 1 of the present invention is observed under a scanning electron microscope, fig. 2 is an SEM image of the gallic acid carbon quantum dot/hydroxypropyl chitosan hydrogel, and it can be seen from fig. 2 that the prepared gallic acid carbon quantum dot/hydroxypropyl chitosan hydrogel shows a loose and porous network structure, and the pore diameter ranges from 20 μm to 70 μm.
Experimental example 3
The mechanical properties of the hydrogels prepared in examples 1 to 3 and comparative examples 1 to 2 were evaluated by using a standard compression test, the hydrogels were made into rectangular solids having a length of 20mm, a width of 20mm, and a height of 15mm, hydrogel samples were placed on a compression mold, and the hydrogel stress was sensed at a constant speed of 5mm/min using a universal tester, the compressive strain was 70%, and the compressive strength was calculated as follows:
P=F/S；
where F is the compression load and S is the compression area.
FIG. 3 is a graph showing stress-strain curves of hydrogels prepared in examples 1-3 and comparative examples 1-2 according to the present invention, wherein the results in the graph show that the compressive strength of the carbon quantum dot/hydroxypropyl chitosan hydrogels prepared in examples 1-3 is generally higher, the maximum compressive stress thereof is 295kPa, 351kPa and 379kPa, respectively, and the compressive strength of the hydroxypropyl chitosan hydrogels prepared in comparative examples 1-2 is significantly lower, and the maximum compressive stress thereof is 181kPa and 209kPa, respectively; comparative example 1 hydroxypropyl chitosan hydrogel without gallic acid had the lowest compressive strength; comparative example 2 is a hydroxypropyl chitosan hydrogel loaded with gallic acid, and the internal crosslinking of the hydrogel can be enhanced due to the complex non-covalent interaction between gallic acid and hydroxypropyl chitosan, and the compressive strength is higher than that of comparative example 1; examples 1-3 are gallic acid carbon quantum dot/hydroxypropyl chitosan hydrogel, the compressive strength of which is in direct proportion to the concentration of the carbon quantum dot, and the carboxyl groups on the surface of the gallic acid carbon quantum dot and the amino groups of the hydroxypropyl chitosan undergo a condensation reaction to form amide bonds, so that covalent crosslinking of the hydrogel can be enhanced, meanwhile, the rich carboxyl groups and hydroxyl groups on the surface of the gallic acid carbon quantum dot and a large number of hydroxyl groups and amino groups on the hydroxypropyl chitosan main chain form electrostatic interactions and hydrogen bond interactions, so that the crosslinking strength of the gallic acid carbon quantum dot/hydroxypropyl chitosan hydrogel is further enhanced, and therefore, the carbon quantum dot/hydroxypropyl chitosan hydrogel has good mechanical properties, and the mechanical strength of the gallic acid carbon quantum dot/hydroxypropyl chitosan hydrogel meets the requirements of hydrogel dressing for treating diabetic wound surfaces.
Experimental example 4
The hydrogels prepared in examples 1-3 and comparative examples 1-2 were evaluated for their antioxidant capacity by DPPH radical scavenging method, DPPH was dissolved in ethanol to prepare solutions with a concentration of 0.05mg/mL, the hydrogels prepared in examples 1-3 and comparative examples 1-2 were prepared into dispersions with different concentrations, respectively, were mixed with DPPH solutions in a volume ratio of 1:1, protected from light, incubated in an oven at 37℃for half an hour, and finally, absorbance of the clear solution at 516nm was measured using an ultraviolet spectrophotometer, and radical scavenging efficiency was calculated according to the following formula:
DPPHscavenging(%)=((A C -A S )/A C )×100；
wherein A is C Represents the absorbance of the DPPH solution; a is that S The absorbance of the DPPH solution after reaction with the sample is shown.
FIG. 4 is a graph showing the DPPH free radical scavenging efficiency of the hydrogels prepared in examples 1-3 and comparative examples 1-2, wherein the graph shows that when the concentration of the carbon quantum dot/hydroxypropyl chitosan hydrogel prepared in examples 1-3 is 10-50 μg/mL, the DPPH scavenging efficiency is 70% or more, the DPPH scavenging efficiency is highest when the concentration is 30 μg/mL, the DPPH scavenging efficiency of the carbon quantum dot/hydroxypropyl chitosan hydrogel prepared in example 3 is about 90% or more, the hydroxypropyl chitosan hydrogel prepared in comparative example 1 does not contain gallic acid, the DPPH scavenging efficiency is about 45%, the hydroxypropyl chitosan hydrogel prepared in comparative example 2 carries gallic acid powder, the DPPH scavenging efficiency is slightly higher than that of the hydroxypropyl chitosan hydrogel prepared in comparative example 1, about 55%, gallic acid has good oxidation resistance, the free radical scavenging ability can be endowed to the hydrogel, the physicochemical properties of the carbon quantum dot prepared from gallic acid can be improved, the physical and chemical properties of the carbon quantum dot can be further enhanced, the surface of the gallic acid carbon quantum dot has a large amount of phenolic hydroxyl groups, the surface of the gallic acid has strong interaction with the free radical, the hydroxypropyl chitosan can have good synergistic effect on the oxidation resistance, and good oxidation resistance can play a positive role in repairing process.
Experimental example 5
The hydrogels prepared in examples 1-3 and comparative examples 1-2 were tested for adhesion by a shear tensile test, pigskin was selected as a representative of skin tissue, the hydrogels prepared in examples 1-3 and comparative examples 1-2 were tested for adhesion to a base material using a universal tester, the contact area of the hydrogels with the different base materials was 30mm×30mm, and the strength of shear adhesion was calculated by dividing the maximum load by the contact area.
Fig. 5 is a graph showing the adhesion performance test of the hydrogels prepared in examples 1-3 and comparative examples 1-2, and it can be seen from the graph that the adhesion strength of the carbon quantum dot/hydroxypropyl chitosan hydrogels prepared in examples 1-3 on the surface of pigskin is 7.1kPa, 8.3kPa and 10.7kPa respectively, and the adhesion strength of the hydroxypropyl chitosan hydrogels prepared in comparative examples 1-2 on the surface of pigskin is lower, 3.5kPa and 4.7kPa respectively, and the adhesion strength of the prepared hydrogels is positively correlated with the concentration of the gallic acid carbon quantum dot, and the phenolic hydroxyl groups rich in the surface of the gallic acid carbon quantum dot can undergo various non-covalent interactions such as hydrogen bond interactions and electrostatic interactions with the tissue surface, so that the adhesion strength is increased, thereby providing good adhesion performance to the hydrogels.
Experimental example 6
This experimental example the hydrogels prepared in examples 1-3 and comparative examples 1-2 were evaluated for their cell compatibility in L929 cells by MTT method, L929 cells were inoculated into 96 well plates at a cell density of 1X 104 cells/well, after 1 day of incubation, 100. Mu.L of fresh medium containing hydrogels prepared in examples 1-3 and comparative examples 1-2 at different concentrations was used for replacing the original medium, deionized water was used as a negative control, normal medium was used as a positive control, incubation was continued for 24 hours, then the medium in the well plates was removed, 50. Mu.L of MTT solution at a concentration of 5mg/mL was added to each well, after incubation for 4 hours in the absence of light, MTT solution was removed, 200. Mu.L of dimethyl sulfoxide was added to each well to develop color, absorbance was read using a microplate reader, and cytotoxicity of the hydrogels was calculated according to the following formula:
Cellviability(%)=(O test -O neg )/(O pos -O neg )×100%；
o in the formula test 、O neg And O pos Absorbance at 570nm was measured for the experimental group, the negative control group and the positive control group, respectively.
FIG. 6 is a graph showing the cell compatibility of hydrogels prepared in examples 1-3 and comparative examples 1-2, wherein the cell viability of the hydrogels prepared in examples 1-3 after incubation with L929 for 24 hours at different concentrations is maintained at 85% or more, and the cell viability of the hydrogels prepared in comparative example 1 after incubation with L929 for 24 hours is maintained at 75% or less, and the cell viability of the hydrogels prepared in comparative example 2 after incubation with L929 for 24 hours is minimized and is lower than 70%; the carbon quantum dot is mainly composed of carbon elements, the carbon elements belong to biological elements and have certain chemical inertness, so that the gallic acid is prepared into the carbon quantum dot, so that the carbon quantum dot has better biocompatibility and low cytotoxicity, in addition, the gallic acid carbon quantum dot has good water solubility and extremely small particle size and molecular weight, is beneficial to the application of the gallic acid carbon quantum dot in organisms, and the gallic acid carbon quantum dot is combined with hydroxypropyl chitosan, so that the biocompatibility of hydrogel is improved.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
The invention and its embodiments have been described above with no limitation, and the invention is illustrated in the figures of the accompanying drawings as one of its embodiments, without limitation in practice. In summary, those skilled in the art, having benefit of this disclosure, will appreciate that the invention can be practiced without the specific details disclosed herein.
Claims (9)
1. A hydrogel dressing for treating a diabetic wound, characterized in that: the hydrogel dressing comprises the following components in parts by weight: 5-10 parts of gallic acid carbon quantum dots, 10-20 parts of hydroxypropyl chitosan, 50-60 parts of deionized water, 1-15 parts of carrageenan and 0.5-5 parts of glycerol; the hydrogel dressing for treating the diabetes wound is mainly prepared by covalent crosslinking of gallic acid carbon quantum dots and hydroxypropyl chitosan;
the preparation method of the gallic acid carbon quantum dot specifically comprises the following steps: dissolving gallic acid in absolute ethyl alcohol, stirring for 15min at room temperature, transferring the mixture into a polytetrafluoroethylene high-pressure reaction kettle, heating at 175-195 ℃ for 5-10 h, naturally cooling the high-pressure reaction kettle to room temperature after the reaction is finished, centrifuging the reaction mixture at 8500rpm for 20min, taking supernatant, removing ethanol solvent by a rotary evaporator, ultrasonically dispersing the product into deionized water, filtering the solution by a microporous membrane with the size of 0.22 mu m, dialyzing for 24h by a dialysis membrane with the interception amount of 500Da, and performing vacuum freeze drying for 24h to obtain purified gallic acid carbon quantum dot powder.
2. A hydrogel dressing for use in the treatment of diabetic wounds according to claim 1, wherein: the size of the gallic acid carbon quantum dot is 1nm-8nm.
3. A method of preparing a hydrogel dressing for use in the treatment of diabetic wounds according to claim 1 or 2, wherein: the method specifically comprises the following steps:
s1, dissolving gallic acid carbon quantum dot powder in ultrapure water, stirring for 15min at room temperature, adding condensing agent 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide, heating to 35-45 ℃, and stirring for 1.6-2h to obtain gallic acid carbon quantum dot solution;
s2, adding a hydroxypropyl chitosan aqueous solution into the gallic acid carbon quantum dot solution prepared in the step S1, stirring for 30min at room temperature to form a carbon quantum dot/hydroxypropyl chitosan mixed solution, reacting under heating, and performing gel forming to obtain a carbon quantum dot/hydroxypropyl chitosan hydrogel;
and S3, adding deionized water, carrageenan and glycerin into the carbon quantum dot/hydroxypropyl chitosan hydrogel obtained in the step S2, and uniformly stirring to obtain the hydrogel dressing.
4. A method of preparing a hydrogel dressing for use in the treatment of diabetic wounds according to claim 3, wherein: in S1, the dosage ratio of gallic acid to absolute ethyl alcohol is 1 g:15-20 mL.
5. The method for preparing the hydrogel dressing for treating the wound surface of diabetes according to claim 4, wherein the method comprises the following steps: in S1, the concentration of the carbon quantum dots in the gallic acid carbon quantum dot solution is 1-5mg/mL.
6. The method for preparing the hydrogel dressing for treating the wound surface of diabetes according to claim 5, wherein the method comprises the following steps of: in S1, the mass ratio of the gallic acid carbon quantum dot, the condensing agent 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and the N-hydroxysuccinimide is 1:4:1.5-2.
7. The method for preparing the hydrogel dressing for treating the wound surface of diabetes according to claim 6, wherein the method comprises the following steps: in the S2, the concentration of the hydroxypropyl chitosan aqueous solution is 3-10mg/mL, and the volume ratio of the carbon quantum dot solution to the hydroxypropyl chitosan aqueous solution is 1:1.5-3.
8. The method for preparing the hydrogel dressing for treating the wound surface of diabetes according to claim 7, wherein the method comprises the following steps of: in S2, the heating temperature is 50-60 ℃ and the heating time is 8-12h.
9. The method for preparing the hydrogel dressing for treating the wound surface of diabetes according to claim 8, wherein the method comprises the following steps of: in the step S3, the stirring temperature is 25-35 ℃ and the stirring time is 2-3h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311100775.1A CN116942892B (en) | 2023-08-30 | 2023-08-30 | Hydrogel dressing for treating diabetes wound surface and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311100775.1A CN116942892B (en) | 2023-08-30 | 2023-08-30 | Hydrogel dressing for treating diabetes wound surface and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116942892A CN116942892A (en) | 2023-10-27 |
| CN116942892B true CN116942892B (en) | 2024-04-02 |
Family
ID=88454763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311100775.1A Active CN116942892B (en) | 2023-08-30 | 2023-08-30 | Hydrogel dressing for treating diabetes wound surface and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116942892B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110669518A (en) * | 2019-11-21 | 2020-01-10 | 中国林业科学研究院林产化学工业研究所 | Fluorescent carbon dot and preparation method and application thereof |
| CN114651919A (en) * | 2022-02-17 | 2022-06-24 | 江南大学 | A method for preparing concentrated citrus juice by hot processing for inhibiting non-enzymatic browning |
| CN115491197A (en) * | 2022-07-05 | 2022-12-20 | 广州新水平量子科技研究有限公司 | Solid fluorescent carbon quantum dot material and preparation method thereof |
| CN116077528A (en) * | 2022-12-30 | 2023-05-09 | 浙江省农业科学院 | Application of gallic acid carbon dots in resisting pseudorabies virus |
-
2023
- 2023-08-30 CN CN202311100775.1A patent/CN116942892B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110669518A (en) * | 2019-11-21 | 2020-01-10 | 中国林业科学研究院林产化学工业研究所 | Fluorescent carbon dot and preparation method and application thereof |
| CN114651919A (en) * | 2022-02-17 | 2022-06-24 | 江南大学 | A method for preparing concentrated citrus juice by hot processing for inhibiting non-enzymatic browning |
| CN115491197A (en) * | 2022-07-05 | 2022-12-20 | 广州新水平量子科技研究有限公司 | Solid fluorescent carbon quantum dot material and preparation method thereof |
| CN116077528A (en) * | 2022-12-30 | 2023-05-09 | 浙江省农业科学院 | Application of gallic acid carbon dots in resisting pseudorabies virus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116942892A (en) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111662464B (en) | Preparation method of chitosan/sodium alginate double-network hydrogel | |
| CN110354295B (en) | Photo-thermal conversion material and preparation method thereof | |
| CN111150880A (en) | Antibacterial composite hydrogel and preparation method thereof | |
| Thangavel et al. | Biomimetic hydrogel loaded with silk and l‐proline for tissue engineering and wound healing applications | |
| Xiong et al. | Bio‐functional hydrogel with antibacterial and anti‐inflammatory dual properties to combat with burn wound infection | |
| CN112300420B (en) | Injectable antibacterial interpenetrating double-network hydrogel and preparation method and application thereof | |
| CN112250887B (en) | Copper metal organic framework nanoparticle functionalized hydrogel and preparation method and application thereof | |
| CN113181421A (en) | Hydrogel wound dressing with antibacterial and immunoregulation functions and preparation method thereof | |
| CN111166931A (en) | Methacrylic acid sericin/chitosan quaternary ammonium salt hydrogel and preparation method and application thereof | |
| CN105228658A (en) | A kind of medical dressing hydrogel compound fabric and its preparation method and application | |
| CN113817181A (en) | Carbon quantum dot modified double-network hydrogel and preparation method thereof | |
| CN108822335B (en) | Composite membrane and preparation method and application thereof | |
| CN113061265A (en) | Polysaccharide hydrogel, preparation method and application thereof | |
| CN114569784B (en) | Folium artemisiae argyi extract-loaded hydrogel and preparation method thereof | |
| CN116440317A (en) | Photothermal antibacterial hydrogel and preparation method thereof | |
| CN113368037B (en) | Bovine lactoferrin peptide nanoparticle-loaded chitosan temperature-sensitive hydrogel and preparation method and application thereof | |
| CN116942892B (en) | Hydrogel dressing for treating diabetes wound surface and preparation method thereof | |
| CN114392390A (en) | Hydrogel wound dressing for tissue repair induced by marine plant extract and preparation method thereof | |
| CN118063636B (en) | Extracellular polysaccharide Riclin-based antibacterial hydrogel as well as preparation method and application thereof | |
| CN108354951B (en) | Oxygen-enriched gel for promoting wound healing, preparation method and application | |
| CN116603097A (en) | Self-repairing injectable hydrogel dressing and preparation method thereof | |
| Zhou et al. | A hydrogel dressing loaded with tea tree oil nanoemulsion accelerates methicillin-resistant Staphylococcus aureus-infected wound healing | |
| CN115845125B (en) | Glycyrrhizinc acid hydrogel loaded with tryptophan carbon quantum dots as well as preparation method and application thereof | |
| CN118416015B (en) | Composition rich in fat stem cell exosomes and application thereof | |
| CN114907583A (en) | Tourmaline particle composite hydrogel and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |